Department of General Biology, Biological Sciences Center, Londrina State University (UEL), Londrina, PR, Brazil.
School of Medicine, Department of Pathology, São Paulo State University (UNESP), São Paulo, SP, Brazil.
Mol Biol Rep. 2021 Sep;48(9):6401-6411. doi: 10.1007/s11033-021-06640-2. Epub 2021 Aug 17.
Obesity is considered a chronic inflammatory disease and transforming growth factor beta 1 (TGFβ1) might exert important roles in disease pathogenesis regulating adipocyte differentiation and immune-inflammatory environment. However, the role of this cytokine as a biomarker in obesity is poorly addressed. Therefore, the present study aimed to evaluate the impact of TGFB1 polymorphisms and TGFβ1 plasmatic levels in obesity METHODS AND RESULTS: TGFB1 promoter region polymorphisms (rs1800468, G-800A and rs1800469, C-509 T) were evaluated in 75 obese patients and 45 eutrophic patients through PCR-RFLP and plasmatic TGFβ1 was quantified through ELISA from 37 of the obese patients, and correlations with clinical and biochemical parameters were tested. Despite no association was found between TGFB1 polymorphisms and obesity susceptibility, several correlations with clinical data were noted. Among others, AC haplotype negatively correlated with plasmatic TGFβ1, while plasmatic TGFβ1 negatively correlated with C-reactive protein and positively correlated with liver abnormalities on ultrasound and, specifically, with steatosis presence and degree. Conversely, GT haplotype, which associates with higher TGFβ1 production, was also positively correlated with the same parameters of liver abnormalities. Further, plasmatic vitamin D negatively correlated with TGFβ1, while positively correlated with AC haplotype.
Overall, the results indicate that TGFβ1 might exert important roles in obesity pathophysiology and correlate with biochemical and clinical parameters both at systemic protein as well as at genetic level. Importantly, the consistent positive correlation at both levels with steatosis might suggest this cytokine as a biomarker for this hepatic abnormality in obese patients.
肥胖被认为是一种慢性炎症性疾病，转化生长因子-β1（TGFβ1）可能在调节脂肪细胞分化和免疫炎症环境方面发挥重要作用，从而影响疾病的发病机制。然而，这种细胞因子作为肥胖标志物的作用尚未得到充分阐明。因此，本研究旨在评估 TGFB1 多态性和 TGFβ1 血浆水平在肥胖中的作用。
通过 PCR-RFLP 评估了 75 名肥胖患者和 45 名正常体重患者 TGFB1 启动子区域多态性（rs1800468，G-800A 和 rs1800469，C-509T），并通过 ELISA 从 37 名肥胖患者中定量测定了 TGFβ1 血浆水平，同时测试了与临床和生化参数的相关性。尽管未发现 TGFB1 多态性与肥胖易感性之间存在关联，但与临床数据存在一些相关性。例如，AC 单倍型与 TGFβ1 血浆水平呈负相关，而 TGFβ1 血浆水平与 C 反应蛋白呈负相关，与超声检查发现的肝脏异常呈正相关，特别是与脂肪变性的存在和程度呈正相关。相反，与 TGFβ1 产生增加相关的 GT 单倍型也与相同的肝脏异常参数呈正相关。此外，TGFβ1 血浆水平与维生素 D 呈负相关，与 AC 单倍型呈正相关。
总体而言，研究结果表明，TGFβ1 可能在肥胖的病理生理学中发挥重要作用，并与系统蛋白和遗传水平的生化和临床参数相关。重要的是，在这两个水平上与脂肪变性的一致正相关可能提示该细胞因子作为肥胖患者这种肝脏异常的生物标志物。
